XSXE:XETRA:XETRA-

| Other Equity |

Last Closing

USD 129.06

Change

+0.34 (+0.26)%

Market Cap

USD 2.55B

Volume

2.25K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-11 )

Largest Industry Peers for Other Equity

Symbol Name Price(Change) Market Cap
8R80:XETRA

+0.60 (+0.42%)

USD 98.84B
XDEE:XETRA

+0.02 (+0.15%)

USD 14.51B
H41H:XETRA

+0.04 (+0.11%)

USD 12.11B
CEB4:XETRA

+0.01 (+0.11%)

USD 11.91B
STXH:XETRA

+0.36 (+0.26%)

USD 6.94B
IBCF:XETRA

+0.12 (+0.09%)

USD 5.81B
MWSH:XETRA

-0.38 (-0.54%)

USD 4.92B
XEWE:XETRA

+0.01 (+0.07%)

USD 3.84B
IBCH:XETRA

+0.13 (+0.14%)

USD 3.29B
WGRU:XETRA

+0.06 (+0.33%)

USD 1.84B

ETFs Containing XSXE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Other Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.33% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 15.62% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.62% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 42.12% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.12% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.43% 68% D+ 67% D+
Dividend Return 11.43% 68% D+ 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.32% 52% F 61% D-
Risk Adjusted Return 92.73% 80% B- 83% B
Market Capitalization 2.55B N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike